Hospitals-acquired Infection Market Research Report Information By Pathogen Types (Viral, Bacterial, and Fungal), By Method of Treatment (Sterilization, Chemical, and Radiation), By Infection Type (Urinary Tract Infections, Blood Stream Infections, Surgical Site Infections, Gastrointestinal Infections, and Respiratory Infections), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2034

Hospitals-acquired Infection Market Overview

As per MRFR analysis, the Hospital-Acquired Infections Market Size was estimated at 30.83 (USD Billion) in 2024. The Hospital-Acquired Infections Market Industry is expected to grow from 31.26 (USD Billion) in 2025 to 35.50 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 1.42% during the forecast period (2025 - 2034).The rising frequency of cervical spondylosis among corporate workers and the increasing occurrences of cervical injuries in vehicle accidents are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In June 2022, the list of COVID-19 disinfectants maintained by the United States Environmental Protection Agency’s List N was supplemented with Nanocyn hospital-grade disinfectant as announced by Sonoma Pharmaceuticals, Inc. and the MicroSafe Group DMCC.

March 2022 saw PDI launching innovative disinfectants—the Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray—to assist infection prevention practitioners in combating increasing health care-associated infections (HAIs) as well as battling continuously against COVID-19.

Additionally, SC Johnson Professional launched its Quaternary Disinfectant Cleaner in a new easy-to-measure squeeze-and-pour bottle in North America in February 2022. Consequently, new product launches are also expected to promote market growth in this segment.

Sodexo, a worldwide company specializing in services that enhance people’s lives, has broadened its relationship with Ecolab for control of healthcare-associated infections (HCAI) via the Protecta Plus initiative within the United States, according to its September 2021 announcement. This program aims at reducing risks associated with infection in hospitals and healthcare facilities through the utilization of Bioquell hydrogen peroxide vapour technology from Ecolab.

June 2021 saw STERIS plc finalize the acquisition of Cantel Medical, a global provider of products and services related to endoscopy equipment, dental supplies, dialysis equipment and life sciences.

Sterigenics S.A.S., a subsidiary of Sotera Health Company, increased European sterilizing capacity expanding its ethylene oxide factory located in Rantigny, France, this year. It is characterized by high capacity and operational reliability comparing with other sterilizers. Sterigenics started selling Getinge Solsus 66 steam sterilizer for use in hospitals as well as surgical instruments during the year 2020.

PURioLABS developed PURitALL, a high-level portable disinfection cabinet to eradicate infection microbes on high-touch equipment and supplies at the point of service and reduce healthcare-associated infections (HAIs) in November 2021. Growth in the market comes from such launches alone.

Additionally, one of the largest instrument processing and surgical supply preparation facilities in Southwest Philadelphia, United States, was opened by Penn Medicine in February 2021 known as the new Interventional Support Center (ISC). For instance, this is one of the first facilities in Pennsylvania where staff will both sterilize and package thousands of instruments each day for surgeries and procedures ranging from basic scissors and clamps to advanced robotic instruments. Market growth is also expected due to such establishments.

Hospitals-acquired Infection Market Trends

• 
  

  Growing Prevalence of spine degeneration to boost the market growth

  
  

Surgery patients, the elderly, and children are more likely to develop hospital-acquired infections. Among the most common infections are those of the respiratory system, surgical sites, the gastrointestinal tract, the urinary tract, the bloodstream, the cardiovascular system, and bones and joints. Hospital-acquired diseases are major causes of death for hospitalized patients and are present in developed and developing nations. The elderly, children and those recently undergoing surgery are more likely to develop hospital-acquired infections. The most common infections are those of the respiratory system, surgical sites, gastrointestinal tract, urinary tract, bloodstream, cardiovascular system, and bones and joints. Both developed and developing nations are affected by hospital-acquired diseases, major factors in hospitalized patients' deaths.

Similarly, the pandemic positively affected the market for diagnostics for hospital-acquired infections, which can be attributed to the rise in hospitalized patients and the spread of infectious viruses that increased the risk of HAIs. The need for hospital-acquired infection diagnostics products also grew due to the risk of infections. Overall, the pandemic thus had a favorable effect on the market for diagnosing hospital-acquired infections. The increase in the prevalence of hospital-acquired infections, increased awareness of hospital-acquired infections, improved healthcare infrastructure, and increased R&D spending are the main factors driving the growth of the hospital-acquired infection diagnostics market share. However, the need for knowledge about hospital-acquired diseases in low- and middle-income countries is a major barrier to the Global market. The market is primarily driven by an increase in infections occurring in clinical settings, particularly in developing economies where facilities for maintaining hygiene are lacking. In contrast, the market for diagnosing hospital-acquired infections predicted a decline in these infections in developed nations like the U.S. S. The development of the hospital-acquired infection diagnostics market is hampered by Germany, and the UK. has enhanced the market CAGR of Hospitals-acquired Infection across the globe in the recent years.

Hospitals-acquired Infection Market Segment Insights

Hospitals-acquired Infection Pathogen Types Insights

The Market segments of Hospitals-acquired Infection, based on Pathogen type, includes Viral, Bacterial, and Fungal. The Fungal segment held the majority share in 2022, contributing to the Hospitals-acquired Infection Market revenue. Anybody can get a fungus infection, manifesting in different body parts. An athlete with athlete's foot, a child with thrush, and a woman with a vaginal yeast infection are just a few examples. The chitin found in the cell walls of fungi distinguishes them from other microorganisms. Like many different kinds of mushrooms, some fungi can be eaten. Aspergillus is a more dangerous fungi species that can cause fatal diseases.

Various types of fungi can bring on fungal infections. Fungi that aren't typically present on or inside your body can occasionally colonize it, resulting in an infection. In other situations, fungi typically found on or inside your body can grow out of control and infect you.

Figure 2: Hospitals-acquired Infection Market by Pathogen Type, 2025 & 2034 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Hospitals-acquired Infection Method of Treatment Insights

The Hospitals-acquired Infection Market segmentation, based on Method of Treatment, includes Sterilization, Chemical, and Radiation. The Sterilization segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Invasive medical procedures—including roughly 5 million gastrointestinal endoscopies—and roughly 46.5 million surgical procedures are carried out annually in the United States. The patient's sterile tissue or mucous membranes are in contact with a medical device or surgical instrument during each procedure. Medical and surgical instruments must be cleaned and sterilized to prevent the transmission of infectious pathogens to patients. Because not all patient care items need to be sterilized, healthcare policies must specify whether cleaning, disinfection, or sterilization is necessary, primarily based on the intended use. Implants for Hospitals-acquired Infections positively impact the market growth.

Hospitals-acquired Infection Infection Type Insights

The Hospitals-acquired Infection Market data has been bifurcated by surgery into Urinary Tract Infections, Blood Stream Infections, Surgical Site Infections, Gastrointestinal Infections, and Respiratory Infections. The Urinary Tract Infections segment dominated the market in 2022 and is projected to be the faster-growing segment during 2022-2030. One of the most typical types of infections in the urinary system is a urinary tract infection (UTI). Your urethra, ureters, bladder, and kidneys are just a few urinary system organs that can become infected with a UTI. Common symptoms include regular urination needs, pain during urination, and side or lower back pain. An antibiotic is a common treatment for UTIs.

Hospitals-acquired Infection Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Hospital-acquired Infection market accounted for USD 13.53 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Due to chronic illnesses and surgeries, the increase in hospital admissions, the burden of hospital-acquired infection combined with the cutting-edge technologies used in infection-control devices, and others.

According to the Centers for Disease Control and Prevention, between 2019 and 2020, there will be a 35 percent increase in ventilator-associated events (VAE) and a 24 percent increase in central line bloodstream infections (CLABSI) in 2021. Thus, the rising prevalence of hospital-acquired infections in the United States spurs regional market expansion. In addition, more people are being diagnosed with chronic conditions like cancer, cancer, and cardiovascular diseases, which necessitate longer hospital stays and more surgeries. For example, the American Health Association estimates that 33,356,853 patients were admitted to hospitals in 2022. Critical procedures like heart bypass surgery and chronic illnesses brought many of these admissions. Therefore, the rising number of hospital admissions is anticipated to increase the demand for infection control products and expand the regional market.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: HOSPITALS-ACQUIRED INFECTION MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s Hospitals-acquired Infection market accounts for the second-largest market share. The high prevalence of HAIs in European nations and the rising approvals and launches of novel HAI therapeutic drugs in the region explains this dominance. Furthermore, due to major companies like GlaxoSmithKline Plc, F.D.A., and others, novel therapeutics for hospital-acquired infections are more readily available in European countries. A.G. Hoffmann-La Roche. Additionally anticipated to support regional growth are Bayer AG, Allergan Plc, and. Further, the Germany market of Hospitals-acquired Infection held the largest market share, and the UK market of Hospitals-acquired Infection was the fastest-growing market in the European region.

The Asia-Pacific Hospital-acquired Infection Market is expected to grow at the fastest CAGR from 2022 to 2030. The high prevalence of HAIs in European nations and the rising approvals and launches of novel HAI therapeutic drugs in the region explains this dominance. Furthermore, due to major companies like GlaxoSmithKline Plc, F.D.A., and others, novel therapeutics for hospital-acquired infections are more readily available in European countries. A.G. Hoffmann-La Roche. Additionally anticipated to support regional growth are Bayer AG, Allergan Plc, and. Moreover, the China market of Hospitals-acquired Infection held the largest market share, and the India market of Hospitals-acquired Infection was the fastest-growing market in the Asia-Pacific region.

Hospitals-acquired Infection Key Market Players & Competitive Insights

Major market players are spending much on R&D to increase their product lines, which will help the market of Hospitals-acquired Infection grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Hospitals-acquired Infection industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the Global Hospitals-acquired Infection industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the Hospitals-acquired Infection industry has provided medicine with some of the most significant benefits. In the Hospitals-acquired Infection market, major players such as Advanced Sterilization Products, Becton Dickinson and Company, Belimed AG, 3M Company, Cantel Medical Corp., Getinge AB, STERIS Corporation., and others are working on expanding the market demand by investing in research and development activities.

Becton Dickinson and Company, The world of health, is advanced by BD, one of the biggest global medical technology providers, by enhancing medical research, diagnostics, and caregiving. By creating cutting-edge technology, services, and solutions that help advance clinical therapy for patients and clinical processes for healthcare providers, the company supports the heroes working on the front lines of healthcare. The 75,000 people who work for BD are passionate about and committed to advancing research that will lead to the next wave of diagnostics and therapeutics. This includes enabling laboratory scientists to detect disease accurately. To tackle some of the most difficult global health issues, BD has a presence in almost every nation and collaborates with international organizations. BD can help improve outcomes, reduce costs, boost efficiencies, boost safety, and increase access to healthcare by closely collaborating with customers.

Also, Cantel Medical Corp. Cantel is a global company that provides cutting-edge infection prevention products and services for patients, caregivers, and other healthcare professionals. Our services and goods enhance results while also preserving life. Cancel offers top-notch infection prevention solutions and unmatched customer service through an extensive endoscopy portfolio, water purification and filtration, and medical disposables. We have an annual impact on millions of patients through our products and solutions. Cancel, the world leader in infection prevention only provides the Complete Circle of Protection. A full-value proactive partnership committed to assisting you in reducing risk, streamlining operational efficiencies, and maximizing your success. The best strategy is starting with the most necessary solution—from procedures, manual cleaning and reprocessing to dry and storage solutions. Our selection of products for preventing infections is extensive.

Key Companies in the market of Hospitals-acquired Infection include

• Advanced Sterilization Products


• Becton Dickinson and Company


• Belimed AG


• 3M Company


• Cantel Medical Corp.


• Getinge AB


• STERIS Corporation.

Hospitals-acquired Infection Industry Developments

November 2020: Sonoma Pharmaceuticals, Inc. and the MicroSafe Group DMCC reported that the COVID-19 list of disinfectants, kept by the United States Environmental Protection Agency's List N, now includes Nanocyn hospital-grade disinfectant.

November 2020: Innovative disinfectants Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray were introduced by PDI in March 2022 to aid infection prevention specialists in the ongoing fight against COVID-19 and the rising number of healthcare-associated infections (HAIs).

Hospitals-acquired Infection Market Segmentation

Hospitals-acquired Infection Pathogen Types Outlook

• Viral


• Bacterial


• Fungal

Hospitals-acquired Method of Treatment Outlook

• Sterilization


• Chemical


• Radiation

Hospitals-acquired Infection Infection Type Outlook

• Urinary Tract Infections


• Blood Stream Infections


• Surgical Site Infections


• Gastrointestinal Infections


• Respiratory Infections

Hospitals-acquired Infection Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America
  
  

Attribute/Metric	Details
Market Size 2024	30.83 (USD Billion)
Market Size 2025	31.26 (USD Billion)
Market Size 2034	35.50 (USD Billion)
Compound Annual Growth Rate (CAGR)	1.42 % (2025 - 2034)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2034
Historical Data	2020 - 2024
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Pathogen Type, Mode of treatment, Infection type, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Belimed AG, 3M Company, Cantel Medical Corp., Getinge AB, STERIS Corporation.
Key Market Opportunities	Rising frequency of cervical spondylosis among corporate workers
Key Market Dynamics	The increasing occurrences of cervical injuries in vehicle accidents